Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses

Cytotherapy

Volumn 13, Issue 4, 2011, Pages 419-430

  Carrade, Danielle D ^a   Owens, Sean D ^a   Galuppo, Larry D ^b   Vidal, Martin A ^b   Ferraro, Gregory L ^c   Librach, Fred ^a   Buerchler, Sabine ^b   Friedman, Michael S ^d   Walker, Naomi J ^a   Borjesson, Dori L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Departments of Surgical and Radiological Sciences   (United States)

^c Center for Equine Health   (United States)

^d Thermogenesis Corp   (United States)

Author keywords

allogeneic; autologous; equine; joint; mesenchymal stem cell

Indexed keywords

CD86 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALLOGENEIC MESENCHYMAL STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL LAMENESS; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS MESENCHYMAL STEM CELL; CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; HORSE; JOINT; JOINT SWELLING; MESENCHYMAL STEM CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SYNOVIAL FLUID;

EID: 79952652661     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.536213     Document Type: Article

References (52)

1. Arnhold SJ, Goletz I, Klein H, Stumpf G, Beluche LA, Rohde C, et al. Isolation and characterization of bone marrow-derived equine mesenchymal stem cells. Am J Vet Res. 2007;68:1095-105. (Pubitemid 47616621)
2. Fortier LA, Nixon AJ, Williams J, Cable CS. Isolation and chondrocytic differentiation of equine bone marrow-derived mesenchymal stem cells. Am J Vet Res. 1998;59:1182-7. (Pubitemid 128472445)
3. Toupadakis CA, Wong A, Gentos DC, Cheung WK, Borjeson DL, Ferraro GL, et al. Comparison of the osteo-genic potentialof mesenchymal stem cells from equine bone marrow, adipose tissue, umbilical cord blood and umbilical cord tissue and optimization of expansion conditions for clinical use. Am J Vet Res; 2010;71:1237-1245.
4. Vidal MA, Kilroy GE, Johnson JR, Lopez MJ, Moore RM, Gimble JM. Cell growth characteristics and differentiation frequency of adherent equine bone marrow-derived mesen-chymal stromal cells: adipogenic and osteogenic capacity. Vet Surg. 2006;35:601-10. (Pubitemid 44526659)
5. da Silva Meirelles L, Sand TT, Harman RJ, Lennon DP, Caplan AI. MSC frequency correlates with blood vessel density in equine adipose tissue. Tissue Eng. 2009;15:221-9.
6. Vidal MA, Kilroy GE, Lopez MJ, Johnson JR, Moore RM, Gimble JM. Characterization of equine adipose tissue-derived stromal cells: adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells. Vet Surg. 2007;36:613-22. (Pubitemid 47480926)
7. Passeri S, Nocchi F, Lamanna R, Lapi S, Miragliotta V, Giannessi E, et al. Isolation and expansion of equine umbilical cord-derived matrix cells (EUCMCs). Cell Biol Int. 2009;33:100-5.
8. Koch TG, Heerkens T, Thomsen PD, Betts DH. Isolation of mesenchymal stem cells from equine umbilical cord blood. BMC Biotechnol. 2007;7:26-35.
9. Koch TG, Thomsen PD, Betts DH. Improved isolation protocol for equine cord blood-derived mesenchymal stromal cells. Cytotherapy. 2009;11:443-7.
10. Schuh EM, Friedman MS, Carrade DD, Li J, Heeke D, Oyserman SM, et al. Identification of variables that optimize isolation and culture of multipotent mesenchymal stem cells from equine umbilicalcord blood. Am J Vet Res.2009;70: 1526-35.
11. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24: 1294-301. (Pubitemid 44464698)
12. Bartholemew S, Owens SD, Ferraro GL, Carrade DD, Lara DJ, Librach F, et al. Collection of equine cord blood and placen-tal tissues in forty thoroughbred mares. Equ Vet J. 2009;41: 724-8.
13. Berg L, Koch T, Heerkens T, Bessonov K, Thomsen P, Betts D. Chondrogenic potentialof mesenchymal stromal cells derived from equine bone marrow and umbilical cord blood. Vet Comp Orthop Traumatol 2009, 22 363-70.
14. Koch T, Berg L, Betts D. Concepts for the clinical use of stem cells in equine medicine. Can Vet J. 2008;49:1009-17.
15. Frisbie D, Smith R. Clinical update on the use of mesenchy-mal stem cells in equine orthopaedics. Equ Vet J. 2010;42: 86-9.
16. Agung M, Ochi M, Yanada S, Adachin, Izuta Y, Yamasaki T, et al. Mobilization of bone marrow-derived mesenchymal stem cells into the injured tissues after intraarticular injection and their contribution to tissue regeneration. Knee Surg Sports Traumatol Arthrosc. 2006;14:1307-14. (Pubitemid 44800660)
17. Black LL, Gaynor J, Adams C, Dhupa S, Sams AE, Taylor R, et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther. 2008;9:192-200.
18. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith C W. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treat ment of osteoarthritis. J Orthop Res. 2009;27(12):1675-80 .
19. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine modelof osteoarthritis. Arthritis Rheum. 2003;48:3464-74. (Pubitemid 37531912)
20. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allerg Drug Targ. 2009;8:110-23.
21. Sotiropoulou PA, Papamichail M. Immune properties of mesenchymal stem cells. Meth Mol Biol. 2007;407:225-43.
22. Kode JA, Mukherjee S, Joglekar MV, Hardikar AA. Mesen-chymal stem cells: immunobiology and role in immunomod-ulation and tissue regeneration. Cytotherapy. 2009;11: 377-91.
23. Koppula PR, Chelluri LK, Polisettin, Vemuganti GK. Histocompatibility testing of cultivated human bone marrow stromal cells: a promising step towards pre-clinical screening for allogeneic stem cell therapy. Cell Immunol. 2009;259(1): 61-5.
24. Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, Taylor PM, et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng. 2006;12:2263-73. (Pubitemid 44734984)
25. Chang CJ, Yen ML, Chen YC, Chien CC, Huang HI, Bai CH, et al. Placenta-derived multipotent cells exhibit immunosup-pressive properties that are enhanced in the presence of interferon-gamma. Stem Cells. 2006;24:2466-77.
26. Keyser KA, Beagles KE, Kiem HP. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant . 2007;16:555-62. (Pubitemid 351448291)
27. + regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92:881-8. (Pubitemid 350144234)
28. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-8. (Pubitemid 34059216)
29. Cui L, Yin S, Liu W, Lin, Zhang W, Cao Y. Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng. 2007;13: 1185-95. (Pubitemid 46986719)
30. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, et al. Identification of IL-10 and TGF beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr. 2007;13:217-26. (Pubitemid 47024153)
31. Yang SH, Park MJ, Yoon IH, Kim SY, Hong SH, Shin JY, et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med. 2009;41:315-24.
32. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005, 2005;105:1815-22. (Pubitemid 40223708)
33. Cho PS, Messina DJ, Hirsh EL, Chin, Goldman SN, Lo DP, et al. Immunogenicity of umbilical cord tissue derived cells. Blood. 2008;111:430-8.
34. Li C, Zhang W, Jiang X, Mao N. Human-placenta-derived mesenchymal stem cells inhibit proliferation and function of allogeneic immune cells. Cell Tissue Res. 2007;330: 437-46. (Pubitemid 350098216)
35. Wang M, Yang Y, Yang D, Luo F, Liang W, Guo S, et al. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology. 2009; 126:220-32.
36. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108:2114-20. (Pubitemid 44395028)
37. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation. 2007;83:783-90. (Pubitemid 46569198)
38. Perin EC, Silva GV, Assad JA, Vela D, Buja LM, Sousa AL, et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine modelof acute myocardial infarction. J Mol Cell Cardiol . 2008;44: 486-95. (Pubitemid 351374698)
39. Wolf D, Reinhard A, Seckinger A, Katus HA, Kuecherer H, Hansen A. Dose-dependent effects of intravenous allogeneic mesenchymal stem cells in the infarcted porcine heart. Stem Cells Dev. 2009;18:321-9.
40. Togel F, Cohen A, Zhang P, Yang Y, Hu Z, Westenfelder C. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev. 2009;18:475-85.
41. Planka L, Gal P, Kecova H, Klima J, Hlucilova J, Filova E, et al. Allogeneic and autogenous transplantations of MSCs in treatment of the physeal bone bridge in rabbits. BMC Biotechnol. 2008;8:70-79.
42. Arinzeh TL, Peter SJ, Archambault MP, van den Bos C, Gordon S, Kraus K, et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am. 2003;85A:1927-35. (Pubitemid 37259728)
43. Prigozhina TB, Khitrin S, Elkin G, Eizik O, Morecki S, Slavin S. Mesenchymal stromal cells lose their immunosup-pressive potential after allotransplantation. Exp Hematol. 2008;36:1370-6.
44. Guest DJ, Smith MR, Allen WR. Monitoring the fate of autol-ogous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study. Equine Vet J. 2008;40:178-81. (Pubitemid 351717168)
45. Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR, et al. Processing and cryopreser-vation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA.1995;92: 10119-22.
46. Anonymous. Definition and classification of lameness. In: Kester, WO. (Eds). Guide for Veterinary Service and Judging Of Equestrian Events. Lexington: AAEP; 1991. p. 19.
47. Lindegaard C, Gleerup KB, Thomsen MH, Martinussen T, Jacobsen S, Andersen PH. Anti-inflammatory effects of intra-articular administration of morphine in horses with experimentally induced synovitis. Am J Vet Res. 2010;71: 69-75.
48. Kay AT, Bolt DM, Ishihara A, Rajala-Schultz PJ, Bertone AL. Anti-inflammatory and analgesic effects of intra-articular injection of triamcinolone acetonide, mepivacaine hydrochlo-ride, or both on lipopolysaccharide induced lameness in horses. Am J Vet Res. 2008;69:1646-54.
49. Oh W, Kim DS, Yang YS, et al. Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. Cell Immunol 2008;251:116-123.
50. Zhang ZY, Teoh SH, Chong MS, et al. Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem Cells 2009;27:126-137.
51. Hu X, Wang J, Chen J, et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg 2007;31:438-443. (Pubitemid 46329387)
52. Del Bue M, Ricco S, Ramoni R, et al. Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: their association in vitro and in vivo. Vet Res Commun 2008;32:S51-5.